People with uncontrolled movement problems can have a harder time doing everyday tasks such as speaking, reading, writing, and cooking, which can cause a loss of independence. This may cause people to ...

A case report indicates that valbenazine may be an effective therapy for chorea-ballism associated with tardive dyskinesia. Valbenazine has therapeutic potential to improve chorea-ballism associated ...

Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

The US Food and Drug Administration (FDA) has approved deutetrabenazine extended-release tablets (Austedo XR, Teva), a new once-daily formulation of the drug for adults with tardive dyskinesia (TD) or ...

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...

Benign hereditary chorea (BHC) is a rare, autosomal dominant neurological disorder characterised by early-onset, non-progressive chorea. Mutations in the NKX2-1 gene, which encodes the thyroid ...

Symptoms of ARF tend to present themselves 1-3 weeks after infection. A high index of suspicion for ARF must be maintained, especially because a single diagnostic tool does not exist. Thomas D. Jones ...

A 59-year-old woman with a background of HIV living with an uncontrollable movement disorder presented to Eoghan Donlon, MB, BCh BAO, MRCPI, of the Mater Misericordiae University Hospital in Dublin, ...